Clinical Trial Update: Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance [Phase 2]

View source ↗

Summary

Phase 2 trial update for ERapa to prevent progression in patients with familial adenomatous polyposis; trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• ERapa

Snippet

Sponsor: Rapamycin Holdings Inc. | Conditions: Familial Adenomatous Polyposis | Phase 2 | Status: ACTIVE_NOT_RECRUITING